{'fraction_non_alphanumeric': 0.051643192488262914, 'fraction_numerical': 0.04107981220657277, 'mean_word_length': 5.991803278688525, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Novel Benzoisoxazoloazepine Inhibitors of Bromodomain-Containing Proteins.

Title: Novel Benzoisoxazoloazepine Inhibitors of Bromodomain-Containing Proteins Patent/Patent Application Number: WO 2013/184876 A1 Publication Date: December 12, 2013 Priority Application: US 2012-61656205 Priority Date: June 6, 2012 Inventors: Albrecht, B. K.; Hewitt, M. C.; Gehling, V. S.; Vaswani R. G. Assignee Company: Constellation Pharmaceuticals, Inc., USA Disease Area: Cancer Biological Target: Bromodomain-containing proteins, BRD4 Summary: The present application claims a series of benzoisoxazoloazepine to serve as inhibitors of bromodomain-containing proteins. The compounds described in this patent application could potentially be useful for the treatment of cancer, inflammatory disease, autoimmune disease, or viral infection. Important Compound Classes: